Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Keratosis, Actinic 12Head and Neck Neoplasms 3Condylomata Acuminata 3Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Exanthema 2Colorectal Neoplasms 2Breast Neoplasms 2Wounds and Injuries 1Warts 1Virus Diseases 1Usual Type Vulval Intraepithelial Neoplasia (uVIN) 1Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Squamous Intraepithelial Lesions 1Skin Neoplasms 1Sexually Transmitted Diseases 1Radiodermatitis 1Parapsoriasis 1Papillomavirus Infections 1Non-Muscle Invasive Bladder Neoplasms 1Non-Melanoma Skin Cancers 1Lymphoma, Follicular 1Keratosis, Seborrheic 1Hypogonadism 1Hemangioma, Cavernous 1Hemangioma 1

Interventions

Gemcitabine 157Cisplatin 116pembrolizumab 80Nivolumab 42Carboplatin 42Paclitaxel 41Mitomycin 41Cystectomy 40Docetaxel 38atezolizumab 33Magnetic Resonance Spectroscopy 31durvalumab 30Radiotherapy 29BCG Vaccine 26avelumab 24Specimen Handling 24Doxorubicin 23enfortumab vedotin 22Fluorouracil 20Cystoscopy 20Methotrexate 17Vinblastine 16Standard of Care 15Filgrastim 14Transurethral Resection of Bladder 13Sunitinib 13Ipilimumab 13vinflunine 125-aminolevulinic acid hexyl ester 12tremelimumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Urinary Bladder Neoplasms × Gels × Clear all
NCT02307487 2017-06-16

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

UroGen Pharma Ltd.

Phase 2 Completed
14 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡